Acute Coronary Syndrome (ACS)

Researchers are evaluating erectile function changes in male patients who undergo percutaneous coronary intervention (PCI) for either a heart attack or stable angina. The study aims to understand how myocardial infarction affects erectile function over time and to explore whether erectile dysfunction can predict future cardiac events. This observational study compares erectile function between patients with myocardial infarction and those with stable angina using standardized questionnaires. Participants are grouped into two sets: those treated with PCI after a heart attack and those treated due to stable angina. Erectile function is assessed at baseline (after recovery from PCI), and at 3 and 6 months post-procedure using the International Index of Erectile Function (IIEF) questionnaire. Additional assessments include the Beck Depression Inventory and Fear of Cardiac Recurrence and Progression Scale. Researchers also collect clinical data such as cardiac vessel scores, ejection fraction, testosterone levels, body measurements, medication use, and the intervention method. During the study, male participants aged 30 to 75 will complete face-to-face interviews and questionnaires at specified intervals: baseline, 3 months, and 6 months after PCI. The study measures changes in erectile function scores over time and examines associations with cardiac health, depression, and anxiety symptoms. Safety and participation are monitored throughout the follow-up period. The total duration of involvement is up to 6 months, with evaluations focusing on erectile function and related health parameters.

Researchers are studying patients with elevated Lipoprotein(a) levels above 30 mg/dL who have undergone percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation but have not experienced cardiovascular events or significant bleeding within 12 months after the procedure. The trial aims to compare whether extending dual antiplatelet therapy (DAPT) from the standard 12 months to 24 months can reduce major adverse cardiovascular and cerebrovascular events such as death, heart attack, and stroke. This randomized, double-blind trial also evaluates if longer DAPT is as safe as the standard duration regarding bleeding and net adverse clinical events. Participants are randomly assigned to one of two groups: one group receives aspirin combined with clopidogrel for 24 months after PCI, while the other group receives aspirin plus a placebo identical to clopidogrel for 12 months. The therapy is delivered as oral medications daily. The study includes a follow-up period with assessments at 3, 6, 9, and 12 months after randomization to monitor outcomes. The trial is conducted across multiple centers with blinded evaluation of results. During the study, participants will undergo regular monitoring to assess cardiovascular events and bleeding incidents, including all-cause death, myocardial infarction, stroke, stent thrombosis, and various bleeding types classified by the Bleeding Academic Research Consortium. Data will be collected through clinical visits and evaluations at predefined intervals up to 12 months after randomization. The research team will analyze these measures to determine the efficacy and safety of extended DAPT in this high-risk population. The total study duration includes treatment and follow-up phases to ensure comprehensive outcome assessment.

Researchers are conducting a registry-based cohort study to observe patients diagnosed with acute myocardial infarction (AMI) who underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, from January 2009 through December 2028. The study aims to gather detailed clinical data and monitor patient outcomes to better understand in-hospital and long-term effects following PCI treatment for AMI. The study involves collecting comprehensive baseline information including clinical characteristics, procedural details, laboratory results, and medication use for each patient. Participants are those who have undergone primary PCI. The clinical endpoints tracked include major adverse cardiovascular and cerebrovascular events (MACCE) during hospitalization and up to two years after PCI. Secondary outcomes include bleeding events, gout flares, and myocardial perfusion impairment during the procedure. Participants will be followed closely during their hospital stay and monitored for up to two years after discharge. Researchers will assess events such as death, recurrent heart attacks, repeat revascularization, heart failure admissions, and cerebrovascular accidents. The study will also evaluate changes in cardiac function over time. Data collection and follow-up visits will help measure safety, effectiveness, and long-term outcomes of primary PCI in AMI patients.

Researchers are evaluating the accuracy of myocardial imaging using integrated 18F-FDG PET/MR to detect viable heart muscle in patients with ischemic heart disease. The study also aims to see if this imaging method can replace the current standard that combines 18F-FDG PET with 99mTc MIBI SPECT/CT gated myocardial perfusion imaging. This is important as assessing heart muscle viability helps predict treatment success and select the best surgical options, especially before coronary artery bypass grafting (CABG). Participants will undergo two procedures within two weeks before surgery: an integrated 18F-FDG PET/MR scan, and a combined 18F-FDG PET/MR plus 99mTc MIBI gated myocardial perfusion imaging. These imaging techniques allow doctors to evaluate heart blood flow, metabolism, muscle vitality, and function simultaneously. The study focuses on patients with significant coronary artery narrowing and reduced heart function, some of whom may also receive stem cell treatments alongside CABG. During the study, participants will sign informed consent and complete the imaging scans, with outcome measures including myocardial perfusion and metabolic imaging assessed approximately two days after the scans. Researchers will monitor heart function and muscle viability to help determine surgical outcomes. The study runs until 2026 and involves adults under 80 years with specific heart conditions, ensuring comprehensive assessments to support future heart disease treatments.

This trial investigates MT1002, a new synthetic peptide designed to work as both a blood thinner and platelet inhibitor, for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The study is open-label and aims to evaluate the safety and dosing of MT1002 in this group of patients. The trial is sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. and is in a Phase 2 stage, focusing on careful dose adjustments and monitoring. Participants receive a single intravenous infusion of MT1002, starting with a loading dose followed by a maintenance dose over 4 hours. The initial dose is 0.60 mg/kg as a bolus, then 1.2 mg/kg per hour for 4 hours. A Safety Review Committee monitors responses to adjust doses as needed to ensure patient safety. This sequential dose escalation and de-escalation process helps identify the appropriate dose range. During the study, participants are closely monitored for blood clotting times (ACT) and major bleeding events from the day of treatment up to 30 days afterward. Researchers collect data on how many patients achieve the target clotting time and track any bleeding complications. The study includes regular assessments and safety follow-up to understand the treatment's impact and side effects over this period.

Researchers are studying patients with acute coronary syndrome who undergo percutaneous coronary intervention to understand the risk factors that affect the occurrence and prognosis of this condition. This observational study will follow participants for at least two years to track major adverse cardiovascular events, including all-cause mortality, cardiovascular mortality, and ischemic stroke. The study is led by Su Guohai and aims to gather comprehensive data to improve knowledge about acute coronary syndrome outcomes. Participants will have blood and fecal samples collected for detailed analysis. Clinical information such as diagnosis, medical history, lab test results, treatment methods, prognosis, and follow-up data will also be recorded. The study focuses on monitoring the progression and outcomes of acute coronary syndrome over time through regular data collection. During the study, participants will be closely followed up to document any major cardiovascular events over a two-year period and beyond. Researchers will assess various health measures and risk factors to better understand how acute coronary syndrome develops and progresses. The total duration of participation includes initial enrollment and ongoing observation to capture long-term outcomes.

This research aims to compare the outcomes of different percutaneous coronary intervention (PCI) strategies in elderly patients with complex, severely calcified coronary artery lesions. The study focuses on patients aged 60 years and older who have significant coronary heart disease involving complex calcified lesions. Researchers want to understand how various PCI methods affect the prognosis, especially the occurrence of major adverse cardiovascular events within one year. Participants are grouped based on the PCI strategy used to treat their coronary lesions. One group receives drug-eluting stents (DES) only, another group receives a combination of DES and drug-coated balloons (DCB), and a third group is treated with DCB alone. All lesions treated involve complex, severe calcification as assessed by imaging techniques. The study observes these treatment approaches as they are applied without altering clinical care. During the study, participants will be monitored for major adverse cardiovascular events over a 12-month period. Researchers will track outcomes such as cardiac death, myocardial infarction, target vessel revascularization, stroke, and specific cardiac events labeled BRCA 2,3-5. Data collection includes clinical assessments and follow-ups to evaluate the one-year prognosis after the PCI procedures. The total duration of participation corresponds with this year-long follow-up.

Researchers are evaluating the potential benefits of implanting an implantable cardioverter defibrillator (ICD) in patients with coronary artery disease who have survived cardiac arrest caused by ventricular fibrillation or sustained ventricular tachycardia. These patients have undergone complete revascularization and have a left ventricular ejection fraction (LVEF) above 35%. The study aims to assess whether ICD implantation can improve survival outcomes compared to standard medical therapy. Participants are randomly assigned to one of two groups: one group receives an ICD implanted either during admission or within 4 weeks after discharge from the initial cardiac event, while the other group receives guideline-directed medical therapy without ICD implantation. The study compares these approaches to understand the effect of ICDs on survival in this patient population. During the study, participants will be monitored for outcomes including all-cause mortality over a five-year period, as well as mortality related to cardiovascular causes at one year. Researchers will collect data on sudden cardiovascular death and cardiovascular death within the first year. The trial includes follow-up assessments to track these outcomes and the overall health of participants throughout the study duration.

This research aims to learn more about vitamin C deficiency in patients with either acute or chronic diseases. It focuses on understanding how symptoms change over time and how well patients tolerate treatment. The study involves patients diagnosed with vitamin C deficiency either by lab tests or based on symptoms such as fatigue, infections, bleeding gums, joint pain, and poor wound healing. The study observes patients treated with Vitamin C Injektopas® 7.5 g, given for an expected average of about 3 weeks for acute diseases or 12 weeks for chronic diseases. Two groups are included: those with acute underlying diseases and those with chronic underlying diseases, both receiving this vitamin C therapy during the study period. Participants will be followed to assess changes in general and disease-specific symptoms, as well as treatment tolerability and overall effectiveness from the patient's perspective. Researchers will also record the number of vitamin C infusions and measure quality of life for chronic disease patients. The study duration ranges up to approximately 12 weeks, with evaluations at the last visit to understand symptom improvement and treatment impact.

Researchers are evaluating a predictive tool called the Multifactorial Dynamic Perfusion Index (MDPI) to estimate the risk of acute kidney injury after cardiac surgery involving cardiopulmonary bypass (CPB). This observational study involves adults and infants undergoing cardiac surgery, aiming to validate the MDPI in adults, develop a version for infants under 20 kg, and explore if the MDPI can predict other complications including mortality. The MDPI combines seven variables measured during CPB, many of which can be modified by the surgical team to potentially improve patient outcomes. The study is divided into three parts: first, validating the MDPI in 800 adult cardiac surgery patients from two centers using existing CPB monitors that collect data such as hematocrit, oxygen delivery, arterial pressure, and transfusions; second, developing a modified MDPI for 200 infants under 20 kg undergoing congenital heart surgery with additional infant-specific variables; and third, investigating whether the MDPI can predict other postoperative issues like low cardiac output, longer ICU stays, bleeding complications, and 30-day mortality. Data collection includes parameters recorded during surgery and postoperative creatinine values. Participants will undergo cardiac surgery with CPB, during which relevant physiological data will be continuously recorded by specialized monitors. After surgery, kidney function and other outcomes will be monitored for up to 48 hours, with extended follow-up for complications and mortality over 30 days. Researchers will analyze how well the MDPI predicts acute kidney injury and other clinical outcomes, aiming to incorporate the MDPI into real-time monitoring devices to guide therapeutic decisions during surgery.